Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Influenza A virus Neuraminidase/NA protein Antibody (NC41)

Catalog #:   RVV24001 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1
Applications: ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RVV24001

Expression system

Mammalian Cells

Species reactivity

Influenza A virus (strain A/Tern/Australia/G70C/1975 H11N9)

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

Neuraminidase, NA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03472

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

NC41

Data Image
References

No indication of highly pathogenic avian influenza infections in Dutch cows., PMID:40458141

Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season., PMID:40307541

Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections., PMID:40286563

Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model., PMID:40267617

Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination., PMID:40265888

Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection., PMID:40230200

A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses., PMID:40193611

Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets., PMID:40186991

Identification of a seasonal influenza vaccine-induced broadly protective neuraminidase antibody., PMID:40178595

Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus., PMID:40145257

A strategy of enhancing the protective efficacy of seasonal influenza vaccines by providing additional immunity to neuraminidase and M2e., PMID:40139072

Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice., PMID:40097766

Influenza A(H5N1) Immune Response among Ferrets with Influenza A(H1N1)pdm09 Immunity., PMID:40023796

Effect of Prior Influenza A(H1N1)pdm09 Virus Infection on Pathogenesis and Transmission of Human Influenza A(H5N1) Clade 2.3.4.4b Virus in Ferret Model., PMID:40023783

Diagnostic Assays for Avian Influenza Virus Surveillance and Monitoring in Poultry., PMID:40006983

A single dose of inactivated influenza virus vaccine expressing COBRA hemagglutinin elicits broadly-reactive and long-lasting protection., PMID:39982912

Evaluation of an N1 NA antibody-specific enzyme-linked lectin assay for detection of H5N1 highly pathogenic avian influenza virus infection in vaccinated birds., PMID:39956396

Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus., PMID:39879304

Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®., PMID:39798434

Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens., PMID:39756216

Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines., PMID:39754936

Identification of a broad-inhibition influenza neuraminidase antibody from pre-existing memory B cells., PMID:39740671

Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections., PMID:39702744

An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus., PMID:39693411

Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions., PMID:39690742

Detection of antibodies against H5 subtype highly pathogenic avian influenza viruses in multiple raccoons in Tokachi District, Hokkaido, Japan, from 2022 to 2023., PMID:39689812

Cross-neutralization of Influenza A by SARS-CoV-2 specific neutralizing antibodies and polyclonal plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A?, PMID:39654774

A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine., PMID:39645432

Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model., PMID:39636110

Highly Pathogenic H5N1 Influenza A Virus (IAV) in Blue-Winged Teal in the Mississippi Flyway Is Following the Historic Seasonal Pattern of Low-Pathogenicity IAV in Ducks., PMID:39599570

Evolutionary analysis of Hemagglutinin and neuraminidase gene variation in H1N1 swine influenza virus from vaccine intervention in China., PMID:39567587

Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2., PMID:39551038

Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy., PMID:39502688

Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017-2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity., PMID:39501522

Efficacy of the H7N9 vaccine as a candidate for the Korean avian influenza antigen bank., PMID:39486146

SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice., PMID:39481241

A human monoclonal antibody targeting the monomeric N6 neuraminidase confers protection against avian H5N6 influenza virus infection., PMID:39402031

Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA., PMID:39379405

Molecular epidemiology and vaccine compatibility analysis of seasonal influenza A viruses in the context of COVID-19 epidemic in Wuhan, China., PMID:39370830

Broadly cross-reactive immune responses in chickens immunized with chimeric virus-like particles of nodavirus displaying the M2e originated from avian and human influenza A viruses., PMID:39341478

Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes., PMID:39324791

Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States., PMID:39319780

COBRA N2 NA vaccines induce protective immune responses against influenza viral infection., PMID:39291424

Vaccine-induced NA immunity decreases viral shedding, but does not disrupt chains of airborne transmission for the 2009 pandemic H1N1 virus in ferrets., PMID:39248566

Prospects for a sequence-based taxonomy of influenza A virus subtypes., PMID:39247559

Enhancing NA immunogenicity through novel VLP designs., PMID:39197219

Efficacy of commercial recombinant HVT vaccines against a North American clade 2.3.4.4b H5N1 highly pathogenic avian influenza virus in chickens., PMID:39012858

A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice., PMID:38990396

An avian-origin internal backbone effectively increases the H5 subtype avian influenza vaccine candidate yield in both chicken embryonated eggs and MDCK cells., PMID:38970848

A(H2N2) and A(H3N2) influenza pandemics elicited durable cross-reactive and protective antibodies against avian N2 neuraminidases., PMID:38961067

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Influenza A virus Neuraminidase/NA protein Antibody (NC41) [RVV24001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only